July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Auranofin mediates mitochondria-lysosome axis dysregulation and inflammatory cell death in human retinal pigment epithelial cells
Author Affiliations & Notes
  • Thangal Yumnamcha
    Ophthalmology, Visual and Anatomical Sciences, School of Medicine, Wayne State University, Detroit, Michigan, United States
  • Swornalata Devi Pukhrambam
    Ophthalmology, Visual and Anatomical Sciences, School of Medicine, Wayne State University, Detroit, Michigan, United States
  • Fayi Yao
    Ophthalmology, Visual and Anatomical Sciences, School of Medicine, Wayne State University, Detroit, Michigan, United States
  • Lalit P Singh
    Ophthalmology, Visual and Anatomical Sciences, School of Medicine, Wayne State University, Detroit, Michigan, United States
  • Footnotes
    Commercial Relationships   Thangal Yumnamcha, None; Swornalata Pukhrambam, None; Fayi Yao, None; Lalit Singh, None
  • Footnotes
    Support  NIH EY023992; Research to Prevent Blindness (RPB); Core Grant P30 EY004068
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 1930. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Thangal Yumnamcha, Swornalata Devi Pukhrambam, Fayi Yao, Lalit P Singh; Auranofin mediates mitochondria-lysosome axis dysregulation and inflammatory cell death in human retinal pigment epithelial cells. Invest. Ophthalmol. Vis. Sci. 2019;60(9):1930.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine the role of the Trx/TrxR redox signaling pathway in human retinal pigment epithelieum (RPE) dysfunction and cell death mechanisms.

Methods :
A human RPE cell line (APRE-19) was cultured in DMEM/F12 medium and treated with auranofin (4 μM, an inhibitor of TrxR) for 4 and 24 h. Mitochondrial and lysosomal functions, cellular oxidative stress and NLRP3 inflammasome activity were measured using cell assays, Western blotting and confocal microscopy. Antioxidants and anti-inflammatory compounds were tested for blocking auronofin effects. Cell death mechanisms (LDH release to culture media) were determined using necroptosis, ferroptosis and pyroptosis inhibitors. P<0.05 was considered significant in statistical analysis.

Results : Auranofin causes mitochondrial dysfunction (Δψm↓ and ATP↓), oxidative stress (H2O2↑) and mitophagic flux to lysosomes. Lysosomal enzyme (cathepsin L) activity is reduced while caspase-1 (NLRP3 inflammasome) activity is enhanced in ARPE-19. These effects of auranofin on ARPE-19 are inhibited by N-acetylcysteine (5 mM, NAC) and partly by a combination of SS31 (mitochondrial anti-oxidant) and anti-inflammatory drugs (amlexanox and tranilast). Auranofin causes LDH release, which is not inhibited by either ferrostatin-1 or necrostatin-1 (ferroptosis and necroptosis inhibitors, respectively). Conversely, auranofin-induced LDH release is reduced by MCC950 and Ac-YVAD-cmk (NLRP3 and Caspase-1 inhibitors, respectively), suggesting a pro-inflammatory cell death by pyroptosis.

Conclusions : The Trx/TrxR redox system is critical for RPE function and cell viability. We previously showed that thioredoxin-interacting protein (TXNIP) is strongly induced in diabetic retinopathy (DR) and inhibits the Trx/TrxR system. Therefore, the results suggest that the TXNIP-Trx-TrxR redox pathway may participate in RPE dysfunction in DR.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×